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The human herpes simplex virus (HSV) protein VP16 induces formation of a transcriptional regulatory
complex with two cellular factors—the POU homeodomain transcription factor Oct-1 and the cell proliferation
factor HCF-1—to activate viral immediate-early-gene transcription. Although the cellular role of Oct-1 in
transcription is relatively well understood, the cellular role of HCF-1 in cell proliferation is enigmatic. HCF-1
and the related protein HCF-2 form an HCF protein family in humans that is related to a Caenorhabditis elegans
homolog called CeHCF. In this study, we show that all three proteins can promote VP16-induced-complex
formation, indicating that VP16 targets a highly conserved function of HCF proteins. The resulting VP16-
induced complexes, however, display different transcriptional activities. In contrast to HCF-1 and CeHCF,
HCF-2 fails to support VP16 activation of transcription effectively. These results suggest that, along with
HCF-1, HCF-2 could have a role, albeit probably a different role, in HSV infection. CeHCF can mimic HCF-1
for both association with viral and cellular proteins and transcriptional activation, suggesting that the
function(s) of HCF-1 targeted by VP16 has been highly conserved throughout metazoan evolution.
When herpes simplex virus (HSV) infects a cell, the virion
protein VP16 initiates a cascade of viral gene transcription that
leads to productive lytic infection. VP16 (also known as
Vmw65 and -TIF) initiates viral gene transcription by direct-
ing formation of a multiprotein transcriptional regulatory com-
plex—the VP16-induced complex—on HSV immediate-early
promoters with two cellular proteins: Oct-1, a POU domain
transcription factor, and HCF-1, a protein involved in cell
proliferation (for reviews see references 6, 21, and 24).
HCF-1 (also known as C1, VCAF, and CFF) is an unusual
protein. It is translated as a large polypeptide of 2,035 amino
acids which undergoes proteolysis at a series of centrally lo-
cated 26-amino-acid repeats, called HCF-1PRO repeats; the
resulting amino (HCF-1N)- and carboxy (HCF-1C)-terminal
polypeptides are stable and remain noncovalently associated
(10, 25, 27) through the activity of two pairs of amino- and
carboxy-terminal self-association sequences (SAS) (29). At its
amino terminus, HCF-1 contains six sequence repeats that are
related to a sequence repeat found in the Drosophila protein
Kelch (1, 32) and are thus referred to as HCF-1KEL repeats;
these repeats form a -propeller structure which is responsible
for binding VP16 and is sufficient to stabilize the VP16-in-
duced complex (12, 28).
HCF-1 is known to be involved in cell proliferation indepen-
dent of viral infection because, in a mutant hamster cell line
called tsBN67, a proline-to-serine point mutation at position
134 (P134S) in the third HCF-1KEL repeat causes a stable
temperature-induced cell proliferation arrest (5). This same
mutation also impairs HCF-1 association with VP16 and sta-
bilization of the VP16-induced complex (5, 28), suggesting that
VP16 targets an activity involved in cell proliferation when it
associates with HCF-1. Although a mutation in the HCF-1KEL
repeat region causes cell proliferation arrest, this region alone
is not sufficient to rescue cell proliferation—a neighboring
basic region is also required (28).
In addition to VP16, the HCF-1KEL repeat region interacts
with two human basic leucine zipper proteins, LZIP (also
known as Luman) and Zhangfei (4, 16, 17, 19). LZIP and
Zhangfei have the same tetrapeptide HCF-1 binding sequence,
(D/E)HXY, as VP16 and, like VP16, fail to associate with the
tsBN67 mutant HCF-1. These results suggest that VP16 mim-
ics cellular proteins in its interaction with HCF-1 and that the
role of HCF-1 in viral proliferation may reflect its role in
cellular proliferation, although the precise mechanisms may
differ in detail (20).
Consistent with an important role in cell proliferation, ele-
ments of HCF-1 are highly conserved in metazoans. For ex-
ample, extracts from the worm Caenorhabditis elegans and the
insects Drosophila and Spodoptera are able to fulfill the re-
quirement for HCF-1 in VP16-induced-complex formation,
implying the presence of functional HCF-1 homologs in those
organisms (9, 26). Indeed, C. elegans contains a functional
HCF-1 homolog called CeHCF that can support VP16-in-
duced-complex formation (15). Human HCF-1, however, dif-
fers in some respects from CeHCF: although the amino- and
carboxy-terminal regions of HCF-1 are highly conserved in
CeHCF, the middle of the protein with its HCF-1PRO repeats
is missing in CeHCF. Thus, CeHCF is much smaller than
HCF-1 (782 versus 2,035 amino acids) and does not undergo
proteolytic processing (15, 31).
Subsequently, a second human HCF protein called HCF-2
was discovered; like CeHCF, it is smaller than HCF-1, and the
amino- and carboxy-terminal regions, but not the middle of the
protein, are conserved (7). Unlike HCF-1 and CeHCF, how-
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ever, the interaction of HCF-2 with VP16 is reportedly weak,
which has led to the conclusion that HCF-2 is unlikely to play
a role in transcriptional activation by VP16 or in HSV infection
(7).
To better understand the relationship of HCF-1 and HCF-2
to each other and to CeHCF, we have compared all three
proteins directly in both in vitro and in vivo assays. We have
found, unexpectedly, that all three full-length HCF proteins
can associate with VP16 and stabilize the VP16-induced com-
plex effectively. Unlike HCF-1 and CeHCF, however, HCF-2
fails to support VP16-induced transcriptional activation effec-
tively in vivo. These and other results suggest that, since hu-
mans diverged from worms during evolution, the HCF family
has grown and diversified in humans.
MATERIALS AND METHODS
Constructs for HCF protein expression in mammalian cells. The mammalian
expression vector pCGN (23) was used for the expression of N-terminal hem-
agglutinin (HA)-HCF fusion proteins (pCGN series). The plasmids used in
this study, pCGNHCF-1Rep, pCGNHCF-1N1011, pCGNHCF-1N1011/P134S,
pCGNHCF-1N380, and pCGNHCF-1N380/P134S, are described in reference 28.
pCGNCeHCFFL and pCGNCeHCFN395 are described in reference 15.
pCGNHCF-2FL and pCGNHCF-2N373 are described in reference 7 and were
kind gifts from A. Wilson (New York University).
HCF chimeras. pCGNHCF2N356/HCF-1N364–1011 was made as follows. A
cDNA sequence corresponding to HCF-2 amino acids 2 to 356 was amplified by
PCR with primers containing XbaI (5) and BsaI (3) restriction enzyme recog-
nition sites (5, GCTCTAGAGCGGCTCCCAGCCTCCTC; 3, GCGGGTCTC
GGTGGTTTCTCAGTATC; the restriction sites are underlined), using
pCGNHCF-2N373 as a template. The HCF-1 cDNA sequence corresponding to
amino acids 364 to 1011 was amplified by PCR from pCGNHCF-1N1011 with a
primer containing a 5 BsaI restriction site and a 3 primer corresponding to
sequences 3 of the HCF-1N1011 coding sequences and 3 BamHI cloning site (5,
GCGGGTCTCGCCACCACCCCCAGCCCG; 3, CAATCAAGGGTCCCCA
AACTC). These two PCR products were digested with the appropriate restric-
tion enzymes and ligated together with a pCGN vector linearized by digestion
with XbaI and BamHI.
pCGNCeHCFN378/HCF-1N364–1011 was made in a two-step procedure as fol-
lows. First, pCGNCeHCFN395 was digested with BamHI and the cohesive end
was flush ended by treatment with DNA polymerase I large (Klenow) fragment.
The linear molecule was subsequently digested with XbaI. The resulting 1,185-bp
XbaI-BamHI CeHCFN395 fragment was inserted into the pCGNHCF-1N1011
vector between the XbaI and PmlI restriction sites, creating pCGNCeHCFN395–
HCF-1N160–1011. The coding sequences between CeHCF amino acid 378 and
HCF-1 amino acid 363 were deleted by oligonucleotide-directed mutagenesis
(11, 33) with the oligonucleotide CTTCTGGATACTATTTTACCACCACCCC
CAGCCCG (CeHCF sequences are underlined).
COS cell transfection and electrophoretic mobility retardation assay. COS
cells were transfected by electroporation with a Bio-Rad Genepulser with an
extender set at 200 mV and 960 F. Twenty-four hours after transfection, the
cells were washed and collected in ice-cold phosphate-buffered saline (PBS) and
lysed in extraction buffer (300 mM NaCl, 100 mM Tris-HCl [pH 8.0], 0.2 mM
EDTA, 10% glycerol, 0.1% NP-40, 1 mM phenylmethylsulfonyl fluoride). The
extracts were normalized to the level of HCF protein after immunoblot analysis
with the anti-HA mouse monoclonal antibody 12CA5. Electrophoretic mobility
retardation assays using the normalized extracts were done as previously de-
scribed (25). Briefly, extracts containing equal amounts of HCF were mixed with
10 ng of VP16C, 5 ng of Oct-1 POU domain, and radiolabled DNA probe
containing an (OCTA)TAATGARAT VP16-responsive sequence from the
HSV ICP0 promoter. Both VP16C and Oct-1 POU were synthesized in Esch-
erichia coli fused to glutathione S-transferase, purified by affinity to glutathione,
and eluted by cleavage with thrombin. The binding mixtures were incubated at
30°C for 30 min, and the resulting VP16-induced complexes were resolved by
electrophoresis through a 4% acrylamide gel as described previously (25).
Transfection and in vivo transcription assay. Transfection of a subclone of
tsBN67 cells called tsBN67HR1 (30) by calcium phosphate coprecipitation, prep-
aration of RNA, and assay of in vivo transcription by RNase protection were
done as previously described (5). Briefly, cells grown at 33.5°C were seeded at
1.2  106/10-cm-diameter dish. After 24 h at 33.5°C, they were transfected with
1 g of the selected HCF expression plasmid (pCGN series), 100 ng of the
internal reference plasmid p4X(AC), and 2 g of the VP16-responsive -glo-
bin-related reporter plasmid pU2/6XTAAT, with or without 80 ng of the
wild-type VP16 expression plasmid pCGNVP16. pUC119 was used as carrier
DNA to normalize the total amount of DNA to 20 g. At 24 h posttransfection,
the cells were washed with PBS containing 2 mM EGTA and further incubated
at 33.5°C for 12 h, after which the cells were harvested and cytoplasmic RNA was
prepared by NP-40 lysis. Each sample was hybridized with radiolabled antisense
-globin (134) and -globin (98) RNA probes and treated with RNases A and
T1. Protected RNAs were separated on a 6% denaturing polyacrylamide gel in
0.5 Tris-borate-EDTA. Signal intensities were quantified using a Fuji BAS1000
phosphorimager. One-third of the collected cells were used for protein extrac-
tion, as described for COS cells above, and for anti-HA immunoblotting to
visualize the expression levels of HCF and VP16.
tsBN67 cell rescue. Rescue of the tsBN67HR1 temperature-sensitive cell pro-
liferation defect was performed similarly to the method previously described (5;
P. Reilly and W. Herr, unpublished results). tsBN67HR1 cells were seeded at
1.5  105/10-cm-diameter dish and incubated at 33.5°C for 24 h. Transfection by
calcium phosphate coprecipitation was performed with 2 g of pCGN HCF
expression constructs, 4 g of pBabe-puro (a puromycin resistance marker), 1 g
of pBabe-lacZ (a -galactosidase expression construct to test the transfection
efficiency), and 13 g of pUC119 carrier DNA. Twenty-four hours after trans-
fection, the cells were washed with 1 PBS–2 mM EGTA and incubated for a
further 24 h before passage and temperature shift as follows. Cells from each
10-cm-diameter dish were split onto three 6-cm-diameter dishes for long-term
incubation with puromycin at the nonpermissive 40°C temperature to measure
rescue of cell proliferation (N) and protein synthesis after extract preparation
(E) and for incubation at the permissive 33.5°C temperature to measure trans-
fection efficiency (P). After 2 days of selection, the E plates were washed and the
cells were collected with ice-cold PBS. The cell pellets were resuspended in
Laemmli sample buffer and boiled for 5 min before being subjected to gel
electrophoresis for immunoblot analysis. The N and P plates were maintained for
14 and 10 days, respectively, with refeeding at 3-day intervals, and then washed
with PBS and fixed with 4% formaldehyde, and colonies were stained with 0.01%
crystal violet solution.
Yeast two-hybrid assay. The reporter Saccharomyces cerevisiae strain YGH1
(MAT ura3-52 his3-200 ade2-101 lys2-801 trp1-901 leu2-3 gal4-542 gal80-538
LYS::GAL1UAS-gal1TATA-HIS3 URA3::gal1-lacZ) has GAL4-responsive HIS3
and lacZ genes. Yeasts were grown in synthetic complete media supplemented as
indicated in Results. YGH1 was first transformed with pGBT9-HCF plasmids
encoding GAL4 DNA-binding domain (DBD) residues 1 to 94 fused to various
HCF coding sequences as C-terminal fusion proteins. pGBT9, pGBT9HCF-
1N380, and pGBT9HCF-1N380/P134S are described by Freiman and Herr (4).
pGBT9CeHCFN395 and pGBT9CeHCFFL contain C. elegans HCF amino acids 2
to 395 and 2 to 782, respectively, cloned between the XbaI-BamHI sites of
pGBT9. pGBT9-transformed yeast was selected by growth in the absence of
tryptophan. Yeast containing the pGBT9HCF series was transformed a second
time with the pGADGH series, in which a GAL4 transcriptional activation domain
(AD) is fused to VP16C (pGADGHVP16C), VP16CE361A (pGADGH
VP16CE361A), LZIP (pGADGHLZIP), and SNF-4 (pGADGHSNF-4) as de-
scribed previously (4, 14; R. Freiman and W. Herr, unpublished results). Trans-
formed yeasts were selected by their ability to grow in the absence of tryptophan
and leucine, and the interaction between the DBD fusion proteins and the AD
fusion proteins was monitored by growth in the absence of tryptophan, leucine,
and histidine.
RESULTS
To compare HCF-1, HCF-2, and CeHCF, we performed a
pairwise comparison of their sequences and assessed their ac-
tivities in three different assays: (i) VP16-induced-complex for-
mation in vitro, (ii) VP16-induced transcriptional activation in
vivo, and (iii) rescue of the tsBN67 cell proliferation defect.
Human and C. elegans HCF protein similarity. Figure 1A
shows a schematic of the human HCF-1 and HCF-2 and the
worm CeHCF proteins. Both HCF-2 and CeHCF lack similar-
ity to the central region of HCF-1 containing the basic, HCF-
1PRO repeat, and acidic regions. The amino-terminal HCF-
1KEL repeat and a pair of HCF-1 subunit self-association
sequences, called SAS1N for the amino-terminal SAS element
VOL. 75, 2001 VP16 ASSOCIATION WITH HCF PROTEINS 12403
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and SAS1C for the carboxy-terminal SAS element (Fig. 1), are
conserved in both HCF-2 and CeHCF (7, 15, 29). Additionally,
CeHCF, but not HCF-2 (7), has sequence similarity to a car-
boxy-terminal nuclear localization signal (NLS) present in
HCF-1 (13).
Figure 1B shows the percent amino acid identity for each
pairwise comparison among HCF-1, HCF-2, and CeHCF for
the HCF-1KEL repeat, SAS1N, and SAS1C regions. The pair-
wise comparison shows that these three regions are all highly
related to each other in these three proteins. HCF-1 and
HCF-2, however, are more closely related to each other than to
CeHCF, suggesting that the human HCF-1 and HCF-2 genes
have resulted from a gene duplication after the divergence of
worms and humans. The progenitor to the human and worm
HCF proteins may have had a structure more similar to the
present structure of HCF-2 and CeHCF. Although in overall
structure CeHCF resembles HCF-2 more than HCF-1 (Fig.
1A), CeHCF is more closely related to HCF-1 than HCF-2 at
the amino acid sequence level in each of the three conserved
regions (Fig. 1B), suggesting that the functions that have been
conserved in CeHCF may more closely resemble those of hu-
man HCF-1 than those of human HCF-2.
As previously noted (29), the sequences of the HCF-1 SAS
elements are conserved in HCF-2 and CeHCF, even though
these proteins are not known to be proteolytically processed.
This observation has suggested that these regions have one or
more functions other than “self-association” or that self-asso-
ciation is important irrespective of HCF proteolysis (29). The
most highly conserved region, however, among all three pro-
teins is the HCFKEL repeat region (Fig. 1B), which is respon-
sible for association with VP16. Thus, when VP16 associates
with HCF-1, it apparently targets the most conserved domain
in the HCF protein family.
All three HCF proteins can support VP16-induced-complex
formation. Figure 2 shows a comparison of the VP16-induced-
complex formation activity of HCF-1, HCF-2, and CeHCF
proteins in an electrophoretic mobility retardation assay with
the Oct-1 DNA-binding POU domain and VP16 lacking the
carboxyl transcriptional AD (VP16C), both synthesized in E.
coli, and a labeled HSV (OCTA)TAATGARAT VP16 re-
sponse element-containing DNA probe. We compared the ac-
tivities of (i) full-length CeHCF and HCF-2; (ii) full-length
HCF-1 lacking the HCF-1PRO repeats, which is smaller than
wild-type HCF-1 and is not processed, resulting in better syn-
thesis and easier normalization; and (iii) the HCF-1–VP16
interaction domain (residues 2 to 380) and corresponding re-
gions of CeHCF (15) and HCF-2 (7). The HCF proteins, all
containing an HA epitope tag at the amino terminus, were
FIG. 1. HCF proteins share sequence similarity in the amino- and carboxy-terminal regions. (A) Schematic diagram of the human HCF proteins
HCF-1 and HCF-2 and the C. elegans HCF protein CeHCF. Above the diagram of HCF-1 are shown the positions of (i) functional regions of
HCF-1 (e.g., VP16-induced complex [VIC] formation and HCF-1 subunit association [SAS1N and SAS1C]) and (ii) structural features of HCF-1
(e.g., HCF-1KEL repeats and basic region). The solid and open triangles indicate active and inactive HCF-1PRO repeats. The tandem solid
arrowheads indicate fibronectin type 3 (Fn3) repeats. Below the diagram of HCF-1 are shown the schematic structures of HCF-2 and CeHCF.
Regions of similarity are aligned by the lines connecting the diagrams. (B) Sequence identity of HCF proteins. The percentage of identical amino
acid residues between each pair of proteins is shown. The sequence used in each comparison was as follows: HCFKEL repeats, HCF-1 (amino acids
[aa] 18–360), HCF-2 (aa 8–353), and CeHCF (aa 29–375); SAS1N, HCF-1 (aa 361–401), HCF-2 (aa 354–393), and CeHCF (aa 376–416); and
SAS1C, HCF-1 (aa 1812–2002), HCF-2 (aa 598–784), and CeHCF (aa 553–749).
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synthesized in monkey COS cells by transient expression (see
Materials and Methods), and whole-cell extracts were pre-
pared. The normalized levels of HCF protein in each extract
used for complex formation are shown in Fig. 2B.
Figure 2A shows the result of the electrophoretic mobility
retardation assay. Addition of the Oct-1 POU domain alone to
the DNA probe results in an Oct-1–POU domain-specific com-
plex (lane 2). Addition of VP16C to the probe, either alone
or in combination with the Oct-1 POU domain, has no evident
effect (lanes 3 and 4). Addition of mock-transfected COS cell
extract to VP16C and the Oct-1 POU domain results in a low
level of slowly migrating complexes (VP16-induced complexes)
formed by endogenous HCF-1 (lane 5). Comparison of VP16-
induced complex formation with that of the HCF-1Rep and
full-length HCF-2 and CeHCF proteins shows that the levels of
complex formation with HCF-2 are similar to those with HCF-
1Rep, both of which are higher than with the CeHCF protein
(lanes 7 to 9, 11 to 13, and 15 to 17). These results show that
all three proteins can support VP16-induced-complex forma-
tion, although HCF-2 is more effective than CeHCF in this
regard.
We were surprised to find that HCF-2 can effectively stabi-
lize the VP16-induced complex, because Johnson et al. (7)
showed that the region of HCF-2 (HCF-2N373) corresponding
to the HCF-1 VP16 interaction domain (HCF-1N380), which in
HCF-1 is sufficient for VP16-induced complex formation, does
not stabilize the VP16-induced complex. We have shown pre-
viously, however, that the region of CeHCF (CeHCFN395) cor-
responding to the HCF-1 VP16 interaction domain has unex-
pectedly weak VP16-induced-complex formation activity (15).
We therefore directly compared the VP16-induced-complex
formation activities of the HCF-2N373 construct used by John-
son et al. (7) and the CeHCFN395 proteins. Consistent with the
previously reported results, both HCF-2N373 and CeHCFN395
had very weak VP16-induced-complex formation activity com-
pared to the HCF-1N380 construct (Fig. 2A, compare lanes 23
to 25 and 27 to 29 with lanes 19 to 21). Indeed, the HCF-2N373
and CeHCFN395 constructs did not support VP16-induced-
complex formation significantly better than the corresponding
mutant HCF-1N380/P134S molecule (5). We do not know why
the HCF-2N373 and CeHCFN395 constructs do not effectively
stabilize the VP16-induced complex, but this inactivity is re-
flected in the inability of these two proteins to bind VP16 in a
coimmunoprecipitation assay (data not shown). Because the
wild-type full-length HCF-2 and CeHCF proteins can stabilize
the VP16-induced complex effectively, we conclude that stabi-
lization of the VP16-induced complex is a conserved function
of these two human and one C. elegans proteins.
HCF-1 and CeHCF, but not HCF-2, can promote VP16-
induced transcription effectively. Because all three HCF pro-
teins can interact with VP16 and stabilize the VP16-induced
complex, we next asked whether the VP16-induced complexes
formed by these three different HCFs can promote VP16-
induced transcriptional activation in vivo. To compare the abil-
FIG. 2. All three HCF proteins can stabilize the VP16-induced complex. (A) VP16-induced-complex formation. COS cell extracts containing
different HCF proteins were analyzed for VP16-induced-complex formation activity with VP16C, the Oct-1 POU domain, and radiolabeled VP16
response element DNA probe, as described in Materials and Methods. Protein-DNA complexes were resolved in an electrophoretic mobility
retardation assay. The positions of the free probe, the Oct-1 POU domain-bound probe, and the VP16-induced complexes (VICs) formed by
different HCF proteins are indicated on the left. Lane 1, probe alone; lane 2, probe with Oct-1 POU domain; lane 3, probe with VP16C. Lanes
4, 5, 7 to 9, 11 to 13, 15 to 17, 19 to 21, 23 to 25, 27 to 29, and 31 to 33 contain the Oct-1 POU domain and VP16C. Lane 5 contains in addition
unprogrammed COS cell extract, and lanes 6 to 33 contain the COS cell extract with HCF protein as indicated. Each set of three titration lanes
contains a twofold titration, and the non-VP16-containing sample contains the most concentrated extract. The position of each VP16-induced
complex is indicated with a dot. , present; , absent. (B) Immunoblot analysis of the COS cell extracts used in the electrophoretic mobility
retardation assay. Extracts containing HA-tagged HCF proteins were resolved by sodium dodecyl sulfate–8% polyacrylamide gel electrophoresis,
transferred to a nitrocellulose membrane, and blotted with the 12CA5 anti-HA antibody. The asterisk on the right indicates a nonspecific band.
The multiple species smaller than 175 kDa in lane 2 are unrelated to HCF-1 but instead reflect 12CA5-specific cross-reacting cellular proteins that
appear only in this sample because it contains the most cell extract after sample normalization.
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ities of different HCF proteins to activate transcription, we
developed an assay in which ectopically expressed HCF pro-
teins were tested for transcriptional activation of a -globin
promoter-reporter construct containing tandem VP16 re-
sponse elements in the presence of full-length VP16. To cir-
cumvent the transcriptional activity of endogenous HCF-1, we
used tsBN67 cells at permissive temperature; under these con-
ditions, the cells proliferate normally but VP16 displays rela-
tively little transcriptional activity compared to wild-type
BHK21 hamster cells (5, 28). The set of HCF protein expres-
sion vectors used for the VP16-induced complex formation
assay shown in Fig. 2 were transiently transfected both with
and without a VP16 expression vector and the experimental
-globin and internal control -globin reporter constructs. Ad-
ditionally, the activities of the wild-type and tsBN67 mutant
HCF-1N subunit (HCF-1N1011 and HCF-1N1011/P134S) were as-
sayed. Levels of reporter mRNA synthesis were measured by
RNase protection analysis. The levels of HCF and VP16 pro-
tein synthesis were monitored by immunoblot analysis as
shown in Fig. 3C. The relative protein expression levels of
HCF proteins are indicated above each lane. The levels of
VP16 synthesis were similar in all samples containing VP16.
Figure 3A shows a representative result of such an assay of
HCF protein activity. Figure 3B shows the averaged quanti-
tated results of two experiments. Without HCF expression
vector transfection (lanes 1 and 2), the presence of VP16
results in little increase in reporter expression, probably owing
in part to the relative inactivity of the endogenous mutant
HCF-1 protein. Consistent with a low level of endogenous
tsBN67 mutant HCF-1 activity, transfection of the tsBN67 mu-
tant HCF-1N1011/P134S expression vector (lanes 5 and 6) re-
sulted in little increased VP16 transcriptional activity. The
most active HCF construct assayed was the HCF-1N1011 con-
struct (lane 4). The transcriptional activity of HCF-1Rep (lane
8) was two- to threefold lower than that of HCF-1N1011 (lane
4), perhaps owing in part to lower levels of protein synthesis
(Fig. 3B). In contrast to these two HCF-1 expression con-
structs, full-length HCF-2 displays much lower activity (com-
pare lane 10 with lanes 4, 6, and 8), even though it was syn-
thesized at high levels, suggesting that, although it can form a
VP16-induced complex effectively (Fig. 2), the resulting com-
plex is not as transcriptionally competent as its HCF-1 coun-
terpart.
In contrast to HCF-2, CeHCF displays significant activity
FIG. 3. VP16 activates transcription in association with HCF-1 and
CeHCF but only weakly in association with HCF-2. (A) Transcrip-
tional activation by VP16 in tsBN67 cells grown at 33.5°C. The cells
were transfected with an HCF expression construct, a VP16 expression
construct, and reporter constructs, and the resulting -globin and
-globin reporter RNAs were probed by RNase protection analysis as
described in Materials and Methods. Odd-numbered samples con-
tained no cotransfected VP16 expression vector. The samples shown
here were normalized to the level of internal control -globin tran-
script. The positions of the RNase-protected fragments corresponding
to -globin (), correctly initiated -globin (), and read-through (RT)
-globin transcripts are indicated on the left. , present; , absent.
(B) Quantitation of relative -globin transcript levels. The intensity of
each band corresponding to the -globin transcript in the samples
containing VP16 was measured by phosphorimager analysis. The tran-
script levels are shown relative to the HCF-1N1011 sample (panel A,
lane 4). The results represent the average of two complete experi-
ments; the CeHCFN395 was uncharacteristically high in the experiment
not shown here (high error bars), and its apparently higher activity
than CeHCFFL shown here is not a true representation of its activity.
(C) Immunoblot analysis of the tsBN67 cell extracts used in the in vivo
transcription assay shown in panel A. Extracts were resolved by sodium
dodecyl sulfate–8% polyacrylamide gel electrophoresis and transferred
to a nitrocellulose membrane, and the HA-tagged HCF and VP16
proteins were detected with the 12CA5 anti-HA antibody. Only the
VP16-containing samples are shown. The position of each relevant
HCF species is indicated with a black dot to the right of each lane. A
long exposure of lane 4 is shown on the right (lane 4). Relative levels
of HCF-protein synthesis are indicated above each lane. Lane 1, no
ectopic HCF protein synthesized.
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(lane 12) even though it originates from a distantly related
organism and does not form a VP16-induced complex as ef-
fectively as the human HCF-2 protein (Fig. 2). This result
suggests that, once formed, a VP16-induced complex contain-
ing CeHCF is more transcriptionally active in mammalian cells
than one containing HCF-2. The pattern of differential tran-
scriptional activity observed with the full-length proteins was
also observed with the HCF-1N380, HCF-2N373, CeHCFN395,
and HCF-1N380/P134S HCFKEL domain proteins (lanes 14, 16,
18, and 20).
Both HCF-2 and CeHCF fail to rescue the tsBN67 cell pro-
liferation defect. The third assay in which we compared the
activities of HCF-1, HCF-2, and CeHCF was rescue of the
temperature-sensitive tsBN67 cell proliferation defect caused
by the P134S missense mutation in HCF-1 (5). This cell pro-
liferation defect can be rescued by both full-length HCF-1 and
the full-length HCF-1N subunit (28). Previous studies with
full-length CeHCF and HCF-2 have provided contrasting re-
sults: CeHCF (15), but not HCF-2 (7), could rescue the tsBN67
cell proliferation defect. The activity of CeHCF was unex-
pected because it lacks the HCF-1-specific basic region, which
is required for HCF-1 rescue of the tsBN67 defect (Fig. 1) (28).
We have since discovered, however, that the original tsBN67
cell population (5) contains a minor population of prolifera-
tion revertants that are able to grow at the nonpermissive
temperature of 40°C (Reilly and Herr, unpublished).
This finding raised the possibility that the unexpected rescue
of tsBN67 cell proliferation by the CeHCF protein might have
FIG. 4. The HCF-2KEL repeat region can participate in rescue of the tsBN67 cell proliferation defect. (A) Colony formation assay. tsBN67 cells
were transfected with different HCF expression plasmids as indicated. After transfection, the plates were incubated at 40°C for 14 days to permit
colony formation. The colonies were visualized by staining them with crystal violet. (B) Schematic diagrams of HCF proteins analyzed and relative
levels of rescue of tsBN67 cell proliferation at 40°C. See the legend to Fig. 1A for a description of the diagrams. Asterisk, P134S tsBN67 point
mutation. (C) Levels of HCF proteins in transfected tsBN67 cells at nonpermissive temperature. Transfected cells (E plates [see Materials and
Methods]) were collected 48 h after transfection and temperature shift to the nonpermissive temperature (40°C) and were used to make protein
extracts. The extracts were resolved by sodium dodecyl sulfate–8% polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane,
and probed with the 12CA5 anti-HA epitope tag antibody to monitor the levels of HA-tagged HCF protein synthesis. The position of each relevant
band is indicated with a black dot. A long exposure of the immunoblot is shown for lanes 2 to 5 (lanes 2 to 5).
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resulted not from the CeHCF protein but rather from growth
of revertant tsBN67 cell colonies in the rescue assay. To test
this hypothesis, we used a subclone of tsBN67 cells called
tsBN67HR1 (30), which is devoid of revertant cells. Figure 4
shows the results of such an experiment. Cell proliferation was
monitored in a colony formation assay in which tsBN67HR1
cells were cotransfected with an HCF expression vector (Fig.
4B) and a puromycin resistance marker, and the colonies were
assayed after growth in the presence of puromycin at 33.5°C
for 10 days to check for transfection efficiency or at 40°C for 14
days to assay rescue of proliferation at nonpermissive temper-
ature (see Materials and Methods). Growth at the permissive
temperature of 33.5°C showed that the transfection efficiencies
were similar in all samples (data not shown).
As expected, cells transfected with the HCF-1N1011 construct
(Fig. 4A, plate 2), but not with the empty vector (plate 1) or
mutant HCF-1N1011/P134S expression vector (plate 3), gener-
ated colonies of tsBN67 cells at 40°C. As previously described
(7), HCF-2 failed to rescue the tsBN67 cell proliferation defect
(plate 4), even though it was synthesized at levels higher than
HCF-1N1011 (Fig. 4C, compare lanes 2 and 6). In contrast to
our previous study (15), however, CeHCF also failed to rescue
the tsBN67 defect in tsBN67HR1 cells (Fig. 4A, plate 5), even
though it also was present at higher levels than the HCF-1N1011
protein (compare lanes 2 and 7; Fig. 4C). We therefore con-
clude that, contrary to our earlier findings (15), CeHCF, like
human HCF-2, does not complement the tsBN67 HCF-1 de-
fect. The apparent rescue by CeHCF in the earlier experiments
may have resulted from higher transfection efficiency with the
CeHCF samples, which was not monitored in those experi-
ments (15).
As mentioned above, HCF-2 and CeHCF lack sequences
corresponding to the basic region of HCF-1, which in HCF-1
are necessary for rescue of the tsBN67 cell proliferation defect
(28). We therefore investigated whether either the HCF-2 or
CeHCF HCFKEL repeat region can functionally replace the
HCF-1 HCFKEL repeat region for rescue of the tsBN67 cell
proliferation defect by exchanging the HCF-1KEL repeats (res-
idues 1 to 363) for the corresponding HCF-2 (residues 1 to
356) or CeHCF (residues 1 to 378) sequences to create HCF-
2/HCF-1 and CeHCF/HCF-1 chimeric proteins (Fig. 4B).
These chimeric proteins were synthesized at levels similar to
those of HCF-1N1011 (Fig. 4C, long exposure of lanes 2, 4,
and 5). As shown in Fig. 4A, the HCF-2/HCF-1 chimera, but
not the CeHCF/HCF-1 chimera, could rescue the tsBN67 cell
proliferation defect to some extent (compare plates 6 and 7
with plate 1). Although not as effective as HCF-1N1011 (plate
2), the activity of the HCF-2/HCF-1 chimera implies that the
HCF-2KEL repeat region has retained some of the cellular
function(s) of the HCF-1KEL repeat region. The reason(s) for
the failure of the CeHCF/HCF-1 chimera to rescue the tsBN67
cell proliferation defect is not clear. The reason could be an
inherent inability of CeHCF to promote mammalian-cell pro-
liferation, or the activity or stability of the CeHCFKEL repeat
region may be temperature sensitive, because the temperature
required for the tsBN67 cell proliferation rescue assay (40°C)
is 20°C higher than the optimal temperature for C. elegans
growth (20°C).
CeHCF interacts with LZIP. The studies described above
show that, whereas CeHCF is functional in the two viral assays
used—VP16-induced-complex formation and transcriptional
activation—it is not active in the one cellular assay used—
rescue of tsBN67 cell proliferation. The results of the rescue of
tsBN67 cell proliferation, however, are problematic, as men-
tioned above. To test CeHCF function in a more defined
molecular assay of cellular function, we tested the ability of
CeHCF to associate with the human leucine zipper protein
LZIP in an S. cerevisiae two-hybrid assay (3). In that assay, we
compared the abilities of the HCF-1 and CeHCF proteins
fused to the GAL4 DBD and LZIP or VP16C fused to the
GAL4 transcriptional AD to activate transcription of the HIS3
gene and thus support growth of HIS3 yeast in the absence of
histidine.
Figure 5 shows the result of this experiment. Four GAL4
DBD fusions to the HCF-1N380, HCF-1N380/P134S, CeHCFN395,
and CeHCFFL proteins were paired with four GAL4 AD fu-
sions to (i) the VP16C protein; (ii) the VP16CE361A mutant
FIG. 5. C. elegans HCF interacts with human LZIP in a yeast two-
hybrid assay. A yeast GAL1-HIS3 reporter strain was transformed with
expression plasmids encoding different HCF proteins fused to the
GAL4 DBD together with an expression plasmid encoding either one
of two known HCF-1 binding proteins (VP16 and LZIP) or nonbinding
proteins (VP16C and SNF-4) fused to a GAL4 AD. (A) Key for
GAL4-AD fusion protein samples shown in panel B. (B) Yeast two-
hybrid assays. The DBD fusion protein used is indicated above each
plate. Successful growth with histidine (His; left half of each plate)
shows that each expression plasmid has no lethal effect. The interac-
tion between a DBD fusion protein and an AD fusion protein is
demonstrated by successful growth in the absence of histidine (His;
right half of each plate).
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(VP16CMut), which fails to associate with HCF-1 (14); (iii)
the human LZIP protein; and (iv) the irrelevant yeast protein
SNF-4. As expected (4, 17), HCF-1N380 (plate 1), but not
HCF-1N380/P134S (plate 2), interacted with the GAL4 AD-
VP16C and the GAL4 AD-LZIP proteins, but both failed to
interact with the GAL4 AD-VP16CMut and SNF-4 proteins.
Like wild-type HCF-1N380, the GAL4 DBD-CeHCFN395 (plate
3), and GAL4 DBD-CeHCFFL (plate 4) proteins interacted
with VP16C and LZIP but not the VP16CMut and SNF-4
fusion proteins. Thus, full-length CeHCF, as well as the
CeHCFKEL repeat region, can associate with LZIP, suggesting
that, like HCF-1, CeHCF possesses the ability to associate with
both a human protein—LZIP—and the protein of a human
viral pathogen—VP16. For unexplained reasons, HCF-2 failed
to associate with either VP16 or LZIP in this yeast two-hybrid
assay, even though it was synthesized at the same levels as
CeHCF (data not shown). Nevertheless, the results shown here
suggest that the association of HCF-1 and CeHCF with both
LZIP and VP16 reflects the conservation of an important ac-
tivity during metazoan evolution.
DISCUSSION
We have characterized and compared three HCF proteins in
their interaction with the viral protein VP16, both in VP16-
induced-complex formation and transcriptional activation and
in their activities in mammalian cells. Our results show that all
three HCF proteins—the human HCF-1 and HCF-2 proteins
and the C. elegans CeHCF protein—can associate with VP16
and form a stable VP16-induced complex with Oct-1 (Fig. 2).
The resulting VP16-induced complexes, however, have differ-
ent activities for transcriptional activation (Fig. 3), raising the
possibility that the two human HCF proteins can have oppos-
ing effects on how VP16 influences the outcome of viral infec-
tion. In contrast to HCF-2, but like HCF-1, CeHCF can both
associate with VP16 and induce transcriptional activation by
VP16 in mammalian cells, even though CeHCF does not nor-
mally interact with VP16, a key regulator of a human patho-
gen. This result suggests that HCF-1 and CeHCF possess a
shared and conserved cellular activity that is used by VP16 to
form a transcriptionally active VP16-induced complex. In con-
trast to our previous findings (15), however, CeHCF fails to
complement the tsBN67 cell proliferation defect, although this
failure may reflect more about the normal growth tempera-
tures of humans and worms than about an inherent difference
in cellular HCF function in these different species.
VP16 discriminates between HCF-1 and HCF-2 but not at
the level of VP16-induced-complex formation. Our results
show that both HCF-1 and HCF-2 can stabilize the VP16-
induced complex effectively. We did not expect this result,
because Johnson et al. (7) had shown that the region of HCF-2
(HCF-2N373) analogous to a minimal region of HCF-1 (HCF-
1N380) that stabilizes the VP16-induced complex (28) is unable
to stabilize the VP16-induced complex effectively. We have
reproduced this result, but when we assayed the full-length
HCF-2 protein, it did stabilize the VP16-induced complex ef-
fectively (Fig. 2). We do not know the reason for the inactivity
of the truncated HCF-2N373 protein. We note, however, that
the HCFKEL repeats only extend to residue 360 in HCF-1 and
residue 353 in HCF-2. Perhaps the 20 carboxy-terminal non-
HCFKEL repeat SAS1N residues in the HCF-2N373 construct,
but not in the HCF-1N380 construct, interfere with VP16-in-
duced complex formation. Alternatively, the carboxy-terminal
SAS1C region of HCF-2 may stabilize the VP16-induced com-
plex, as has been described previously under certain conditions
for HCF-1 (12).
Whatever the reason for the failure of the HCF-2N373 pro-
tein to stabilize the VP16-induced complex, the ability of the
full-length wild-type HCF-2 protein to stabilize the VP16-in-
duced complex has important implications for our understand-
ing of the interplay of HCF-1 and HCF-2 with VP16 in human
cells. The activity of the wild-type HCF-2 protein suggests that
HCF-2 association with VP16 may influence the outcome of
HSV infection, by either promoting or inhibiting lytic or latent
infection.
Surprisingly, although HCF-2 can stabilize the VP16-in-
duced complex effectively, it fails to support activation of tran-
scription by VP16. Thus, HCF-1 and HCF-2 have dramatically
different activities as a result of their association with VP16, in
one instance (HCF-1) activating transcription and in the other
instance (HCF-2) failing to do so effectively (Fig. 3). We do not
know the reason for the difference in transcriptional activity by
HCF-1 and HCF-2. One possibility is that HCF-2 lacks a car-
boxy-terminal NLS found in HCF-1 (Fig. 1) and the localiza-
tion of HCF-2 is variable after transient overexpression (7).
We do not favor this hypothesis, however, because HCF-1,
which is a chromatin-bound protein, does not require the NLS
for either nuclear localization or chromatin association (30) or
for transcriptional activation with VP16 in either yeast (28) or
mammalian cells (Fig. 3, HCF-1N1011). Furthermore, when
stably synthesized in HeLa cells without overexpression,
HCF-2 is also associated with nuclear chromatin (J. Wysocka
and W. Herr, unpublished results). We therefore favor the
hypothesis that an HCF-2-containing VP16-induced complex is
able to bind appropriately to a VP16-inducible promoter but
that the complex is inactive either because HCF-2 lacks an
essential activity present in HCF-1 or because it possesses an
inhibitory activity not present in HCF-1. For example, cyclin-
dependent kinase activity is required for transcriptional acti-
vation by the VP16-induced complex (8). Perhaps an HCF-2-
containing VP16-induced complex is not able to respond to
cyclin-dependent kinase activity. Whatever the reason, the rel-
ative inability of HCF-2 to activate transcription compared to
HCF-1 suggests that HCF-2 might inhibit VP16 function and
thus perhaps either inhibit lytic infection or promote latent
infection by HSV.
HCF-2 may also serve as an inhibitor of HCF-1 function in
the uninfected cell. Johnson et al. (7) showed that full-length
wild-type HCF-2 can inhibit the ability of wild-type HCF-1 to
rescue the temperature-sensitive tsBN67 cell proliferation de-
fect. Because we have shown here that HCF-1 and HCF-2 can
associate similarly with VP16, it is plausible that HCF-2 can
also associate similarly with cellular targets of HCF-1 but, as
with VP16, display different activities with the shared targets.
The differences in HCF-1 and HCF-2 activity may result
from differences in the regions conserved between the two
proteins, such as the HCFKEL repeat region, or in the se-
quences that are not conserved between the two proteins, such
as those corresponding to the HCF-1-specific basic region that
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are essential for tsBN67 cell rescue by HCF-1 (28). Indeed,
both of these possibilities may play a role in the inhibition of
HCF-1 rescue of the tsBN67 cell proliferation defect by
HCF-2, because when the HCF-2 Kelch repeat region is fused
to the HCF-1 SAS1N and basic regions, the chimeric HCF-2/
HCF-1 protein displays an ability to rescue the tsBN67 cell
proliferation defect that is intermediate between those of
HCF-1 and HCF-2 (Fig. 4). The finding that the HCF-2KEL
repeat region cannot functionally replace the HCF-1KEL re-
peat region to wild-type levels suggests that other functions of
the HCF-1KEL repeat region in addition to association with
cellular VP16-like binding activities are required to promote
cell proliferation, as suggested previously by Mahajan and Wil-
son (20). In summary, the family of mammalian HCF-1 and
HCF-2 proteins may represent a pair of regulators of cell
proliferation that counteract each other’s activities.
C. elegans HCF shares properties of human HCF-1 and
HCF-2. In contrast to human cells, C. elegans has only one
evident HCF-like protein (15). The overall structure of this
protein more closely resembles human HCF-2 (Fig. 1A), but in
some features CeHCF more closely resembles human HCF-1,
including amino acid sequence similarity (Fig. 1B) and VP16
transcriptional activation (Fig. 3). Like both HCF-1 and
HCF-2, however, it is able to associate effectively with VP16.
Because VP16 is an activator of the lytic pathway of a human
viral pathogen not known to exist in worms, we believe that the
ability of CeHCF to associate with VP16 is due to a cellular
protein-protein interaction that has been conserved between
humans and worms and that is mimicked by VP16. Underscor-
ing the significance of this observation is the finding that, in
contrast to HCF proteins, the other cellular component of the
VP16-induced complex—Oct-1—has not conserved its ability
to associate with VP16 even in a species as closely related to
humans as mice, much less in invertebrates (2, 22).
A potential conserved cellular target of HCF proteins is
LZIP, which, like VP16, can associate with both HCF-1 and
CeHCF. Unlike in Drosophila, however, which contains the
LZIP-like protein BBF-2/dCREB-A (4, 17), there is no evident
LZIP homolog in worms (S. Lee and W. Herr, unpublished
results). Furthermore, there is no known C. elegans homolog of
the second human HCF-1-interacting protein called Zhangfei
(19). One possible explanation for the lack of evident conser-
vation of LZIP and Zhangfei homologs in C. elegans is that the
family of HCFKEL repeat-interacting proteins in human cells is
larger than presently known. Consistent with this hypothesis,
and in contrast to LZIP (18) and Zhangfei (19), HCF-1 is an
abundant human protein, and it is entirely tethered to chro-
matin through its VP16 interaction domain, suggesting that
other human proteins are also involved in tethering HCF-1 to
chromatin (30). We suggest that one or more of these other
proteins have homologs in C. elegans that are involved in
shared activities of HCF-1 and CeHCF.
The hybrid nature of CeHCF compared to the human
HCF-1 and HCF-2 proteins suggests that it performs functions
in the worm that in human cells are performed by either
HCF-1 or HCF-2. Determination of those functions should
help elucidate the function of the human HCF proteins, one of
which at least—HCF-1—plays a critical role in human cell
proliferation and HSV pathogenesis.
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